

Correction

**Correction: UBE2T knockdown inhibits gastric cancer progression****Changjiang Luo<sup>1,\*</sup>, Yunyi Yao<sup>2,\*</sup>, Zeyuan Yu<sup>1</sup>, Huinian Zhou<sup>1</sup>, Lingyun Guo<sup>1</sup>, Junqiang Zhang<sup>1</sup>, Hongtai Cao<sup>1</sup>, Genyuan Zhang<sup>1</sup>, Yumin Li<sup>1</sup> and Zuoyi Jiao<sup>1</sup>**<sup>1</sup>Department of General Surgery, Lanzhou University Second Hospital and Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou, Gansu, 730030, China<sup>2</sup>Department of Medical Technology and Key Laboratory of Biotechnology for Laboratory Medicine of Suzhou, Suzhou Vocational Health College, Suzhou, Jiangsu, 215009, China

\*These authors contributed equally to this work

**Published:** March 11, 2023**Copyright:** © 2023 Luo et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has been corrected:** In Figure 4C, in the SGC-7901 panel, the first image in the first row is an accidental duplicate of the third image in the second row. The corrected Figure 4, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.Original article: Oncotarget. 2017; 8:32639–32654. <https://doi.org/10.18632/oncotarget.15947>

